NCT06222437

Brief Summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
8mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Feb 2026Feb 2027

First Submitted

Initial submission to the registry

January 16, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 24, 2024

Completed
2 years until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Expected
Last Updated

March 23, 2026

Status Verified

January 1, 2026

Enrollment Period

Same day

First QC Date

January 16, 2024

Last Update Submit

March 19, 2026

Conditions

Polycystic Ovary Syndrome

Outcome Measures

Primary Outcomes (2)

  • Number of appropriate weekly dose

    To access the compliances of the therapy

    4 weeks

  • Number of days on therapy

    To access the persistence on Semaglutide

    4 weeks

Secondary Outcomes (2)

  • measure the Weight in kilograms

    4 weeks

  • Numbers of days with exercise changes

    4 weeks

Study Arms (1)

Protocol group

EXPERIMENTAL

PCOS women in the age 18 to 45 years

Drug: Semaglutide

Interventions

SemaglutideDRUG

effectiveness of semaglutide in PCOS

Protocol group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailswomen with PCOS
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-45
  • Body mass index(BMI) \> 30
  • Diagnosis of PCOS
  • Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone

You may not qualify if:

  • Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
  • Letrozole, clomiphene citrate, FSH therapy
  • Androgen receptor blockers
  • α reductase inhibitors
  • Insulin
  • Hysterectomy
  • Endometrial ablation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases
0

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2024

First Posted

January 24, 2024

Study Start

February 1, 2026

Primary Completion

February 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

March 23, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

US(1)